GlassScriptPhysician profile
James S Bicknell
NPI 1457389314
$1,670.11
in general payments reported to CMS, 2019-2025
24 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $244 · 2021: $301 · 2022: $261 · 2023: $85.48 · 2024: $210 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $422.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $356.63 | 2021-2022 | |
| Medical Device Business Services, INC. | $239.45 | 2019-2021 | |
| Pacira Therapeutics, INC. | $200.19 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $93.72 | 2022-2024 | Exparel, Zilretta, Iovera |
| Medtronic, INC. | $76.55 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $61.67 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $61.18 | 2025 | |
| Orthalign INC | $55.11 | 2024 | Orthalign Plus |
| Sanofi-Aventis U.S. LLC | $54.38 | 2020 | |
| Horizon Therapeutics Plc | $49.86 | 2019-2020 | |
| Innovation Technologies INC | $49.01 | 2024-2025 | Irrisept |
| Bioventus LLC | $45.63 | 2024-2025 | Durolane |
| Avanos Medical | $44.21 | 2020-2023 | Trivisc Sodium Hyaluronate |
| Midsouth Orthopedics INC. | $43.48 | 2020 | |
| Alafair Biosciences, INC. | $37.44 | 2023 | Versawrap |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $35.65 | 2024 | Arista Ah Flexitip |
| Fidia Pharma USA INC. | $31.34 | 2019-2020 | |
| Smith+Nephew, INC. | $27.21 | 2019 | |
| Averitas Pharma INC. | $26.66 | 2024 | Qutenza |
| Ferring Pharmaceuticals INC. | $26.23 | 2019 | |
| Solventum Corporation | $16.45 | 2025 | Prevena |
| Amgen INC. | $13.47 | 2020 | |
| Mallinckrodt Enterprises LLC | $12.59 | 2019 | |
| Alexion Pharmaceuticals, INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bicknell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.